A prospective observational study of biomarkers for Second-line FOLFIRI plus Aflibercept treatment in patients with metastatic colorectal cancer comparing to FOLFIRI plus beVacizumab: an Exploratory biomarker study.

A prospective observational study of biomarkers for Second-line FOLFIRI plus Aflibercept treatment in patients with metastatic colorectal cancer comparing to FOLFIRI plus beVacizumab: an Exploratory biomarker study. - SAVE Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038508

Enrollment

Registered

2019-11-06

Start date

2019-11-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Unresectable advanced and/or recurrent colorectal cancer with pathological diagnosis. RAS mutation status has been veryfied and was wild type in the primary or metastatic tumor. In the previous treatment, CPT-11, bevacizumab and aflibercept has not been used. There is at least one measurable lesion. PS 0-2

Exclusion criteria

Exclusion criteria: Having an infection which needs systemic treatment

Design outcomes

Primary

Measure	Time frame
Overall response rate of FOLFIRI + aflibercept in patients with TAM-positive colorectal cancer.	—

Countries

Japan

Contacts

Public ContactJunichi Matsubara

Kyoto University Hospital Therapeutic oncology

jmatsuba@kuhp.kyoto-u.ac.jp075-751-3518

Outcome results